Long-term treatment with Duvyzat (givinostat) may help delay the loss of walking ability and lessen the decline in lung ...
Clinical Trials Arena on MSN9h
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...
Traditionally, stock market corrections have been the perfect time for long-term-minded investors with ample cash on hand to ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...
Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...
For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...
Wave Life Sciences (WVE) stock rises on plans to file for FDA accelerated approval of WVE-N531 in 2026, targeting Duchenne muscular dystrophy. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback